Objective To investigate the role of interleukin-18 (IL-18 )and interleukin-33 (IL-33 )in the pathogenesis of bronchial asthma.Methods 40 cases with acute attack of bronchial asthma admitted in Wuhan Third Hospital from March 2011 to January 2012 were chosen as the hormone group,and 30 cases healthy people in the same period who underwent routine physical exa mination were chosen as control group.The serum levels of IL-18 and IL-33,the rate of forced expiratory volume in one second(FEV1 )and forced vitalcapacity(FVC,FEV1%),the number of eosinophil cells(EOS)and immunoglobulin E(IgE)were detected in control group and hormone group before and after treatment.Compare the serum levels of IL-18 and IL-33 in hormone group before and after treatment,and the relevance between IL-18,IL-33 and IgE,EOS and FEV1%. Results Compared with control group,the serum levels of IL-18 and IL-33 in hormone group pre-treatment were significantly increased(P<0.05),FEV1%,EOS and IgE had significant difference(P<0.05).Compared with hormone group pre-treatment the serum levels of IL-18 and IL-33 in hormone group post-treatment were significantly decreased(P<0.05),FEV1%,EOS and IgE improved significantly (P<0.05).Compared with control group,the serum levels of IL-18, IL-33,FEV1% and IgE in hormone group post-treatment had no significant difference.The pearson correlative analysis showed that there were positive correlations between the levels of IL-18,IL-33,IgE and EOS,respectively(P<0.05),and there were negative correlations between IL-18,IL-33 levels and FEV1%,respectively(P<0.05).Conclusion IL-18 and IL-33 participate in the acute asthma,and may play stimulation role in the inflammatory process of asthma.

To evaluate the safety and efficacy of neoadjuvant radiohormonal therapy for oligometastatic prostate cancer (OMPC), we conducted a 3 + 3 dose escalation, prospective, phase I/II, single-arm clinical trial (CHiCTR1900025743), in which long-term neoadjuvant androgen deprivation was adopted 1 month before radiotherapy, comprising intensity modulated radiotherapy to the pelvis, and stereotactic body radiation therapy to all extra-pelvic bone metastases for 4-7 weeks, at 39.6, 45, 50.4, and 54 Gy. Robotic-assisted radical prostatectomy was performed after 5-14 weeks. The primary outcome was treatment-related toxicities and adverse events; secondary outcomes were radiological treatment response, positive surgical margin (pSM), postoperative prostate-specific antigen (PSA), pathological down-grading and tumor regression grade, and survival parameters. Twelve patients were recruited from March 2019 to February 2020, aging 66.2 years in average (range, 52-80). Median baseline PSA was 62.0 ng/mL. All underwent RARP successfully without open conversions. Ten patients recorded pathological tumor down-staging (83.3%), and 5 (41.7%) with cN1 recorded negative regional lymph nodes on final pathology. 66.7% (8/12) recorded tumor regression grading (TRG) -I and 25% (3/12) recorded TRG-II. Median follow-up was 16.5 months. Mean radiological progression-free survival (RPFS) was 21.3 months, with 2-year RPFS of 83.3%. In all, neoadjuvant radiohormonal therapy is well tolerated for oligometastatic prostate cancer.
Male ; Humans ; Prostatic Neoplasms/radiotherapy* ; Prostate-Specific Antigen/therapeutic use* ; Neoadjuvant Therapy ; Androgen Antagonists/therapeutic use* ; Prospective Studies